New eye drops aim to boost blood flow in diabetic retinopathy and glaucoma

NCT ID NCT07354477

First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early study tests whether QLS-111 eye drops can improve blood flow to the back of the eye in people with non-proliferative diabetic retinopathy or certain types of glaucoma. Fourteen participants will use the drops twice daily for two weeks. The main goal is to measure changes in blood flow and vessel size using eye imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
QLS-111 ophthalmic solution
What this could lead to
If it works, this could point toward a new eye drop that improves blood flow in the back of the eye, potentially helping to manage diabetic retinopathy and glaucoma.
What could go wrong
This is a very small, early pilot study with only 14 participants. It is designed to test blood flow changes, not to prove the drops treat or cure the disease. The results may not lead to a treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-PROLIFERATIVE DIABETIC RETINOPATHY (NPDR) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford University, Dept. of Ophthalmology

    RECRUITING

    Palo Alto, California, 94303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.